Sintilimab Not Yet Recruiting Phase 4 Trials for Unresectable Hepatocellular Carcinoma (HCC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT05660213Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)